About Michelson Diagnostics
Michelson Diagnostics (MDL) is a UK-based independent company with products based on an optical imaging technology, called 'Multi-Beam OCT'. The company is primarily targeting cancer (screening, diagnosis, staging, treatment planning and guidance, and monitoring), but the products are also finding applications in commercial skin products research, in genetics (developmental biology) and in industrial metrology.
Michelson Diagnostics Patents
Michelson Diagnostics has filed 12 patents.
Dermal and subcutaneous growths, Angiology, Rare diseases, Vascular diseases, Laser medicine
Dermal and subcutaneous growths, Angiology, Rare diseases, Vascular diseases, Laser medicine
Latest Michelson Diagnostics News
Aug 24, 2023
Michelson Diagnostics Limited Strategic Development On 25 July 2022, STRATA Skin Sciences, Inc., a healthcare technology company focused on developing, commercializing, and branding innovative products for the treatment of dermatologic conditions, announced the commercial launch in the United States of TheraClearX, a non-invasive, in-office acne treatment that targets the underlying causes of mild to moderate acne, such as comedonal, pustular as well as inflammatory acne vulgaris. On 1 June 2022, Cynosure introduced the PicoSure Pro gadget, the newest addition to the PicoSure system. The PicoSure Pro device, an FDA-cleared 755nm picosecond laser, produces energy in a trillionth of a second, employing pressure rather than heat to offer safe as well as efficient solutions for undesired pigmentation and skin renewal for all skin types. You can conveniently place your order directly through this provided link @ https://www.emergenresearch.com/select-license/1462 Some Key Highlights From the Report The treatment devices segment is expected to account for the largest revenue share during the forecast period which is attributed to the accessibility of a wide range of dermatological treatment options and introduction of innovative laser device technologies. For example, Lumenis Ltd., the world's leading producer of energy-based medical devices for cosmetic, surgical, and ophthalmic applications, launched the NuEra Tight with FocalRF technology on 17 August 2020. The technology provides a breakthrough in personalized non-invasive RF body treatments that are tailored to each patient's exact demands, helping to drive market revenue growth. The diagnostic devices segment is expected to register a steady CAGR during the forecast period. It is further sub-segmented into skin cancer diagnosis and others. Given the rise in skin cancer prevalence, the sub-segment of skin cancer diagnosis has the largest revenue share. Furthermore, new research and development on skin cancer diagnostics is driving market revenue growth. For example, roughly 3.3 million individuals in the United States are diagnosed with basal and squamous cell carcinomas each year. URSKIN is a device created by researchers at Huntsman Cancer Institute (HCI) and the University of Utah that employs a technology known as non-visual electrical impedance demography to exploit changes in the electrical properties of skin that occur during cancer cell proliferation (EID). Market in North America is expected to account for the largest revenue share during the forecast period, which is attributed primarily to rising frequency of skin cancer and other skin conditions such as atopic dermatitis and psoriasis, as well as widespread awareness of cosmetic operations. Acne, for example, is the most common skin condition in the United States, affecting up to 50 million individuals each year. Acne affects around 85 percent of individuals between the ages of 12 and 24. According to recent studies, about 8 million individuals in the United States suffer from psoriasis. As a result, the region's expanding prevalence of skin disorders is rising demand for dermatological devices. Feel free to explore the complete report description, research methodology, table of contents, and accompanying infographics by following this link @ https://www.emergenresearch.com/industry-report/dermatology-devices-market Emergen Research has segmented the global dermatology devices market on the basis of product, application, end-use, and region: Product Outlook (Revenue, USD Billion; 2019–2030) Diagnostic Devices Diagnostic Devices Hospitals North America Curated Reports You Shouldn't Miss: Dive In Now! Electrosurgical Devices Market By Method (Bipolar, Monopolar), By Product (Active electrodes, Electrosurgical Generators, Electrosurgical Instruments and Accessories), By Surgery Type (General surgery, Cosmetic, Cardiovascular), Forecasts to 2027 Interventional Cardiology Market By Product (Catheters, Angioplasty Balloons, Plaque Modification Devices, Angioplasty Stents), By End Users (Cardiac Catheterization labs, Hospitals, Ambulatory surgical centers), Forecasts to 2027 Injectable Drug Delivery Market , By Device Type (Conventional Injectables, Pre-Filled Syringes, Auto-Injectors, Pen-Injectors), By Product Type (Freeze-Dried Products, Injectable Sterile Products), By End-use, and By Region Forecast to 2030 Molecular Diagnostics Market , By Product & Services (Reagent, Instrument, Software & Service), By Technology (Polymerase Chain Reaction), By Application, By End-Use, By Test Location, and By Region Forecast to 2030 Teleradiology Services Market By Imaging Technique (MRI, CT, X-Rays, Ultrasound, Mammography), By End-Users (Diagnostic Centers, Hospitals & Clinics), By Products and Services (Software, Hardware, Teleradiology services), Forecasts to 2027 Biomaterials Market By Type (Ceramic, Metallic, Polymeric, Natural, Others), By Application (Cardiovascular, Ophthalmology, Orthopedic, Plastic Surgery, Neurology, Others), and Regions Forecasts to 2027 Phototherapy Devices Market By Product (LED, Fibreoptic, Conventional Phototherapy Devices), By Application (Neonatal Jaundice Management, Skin Disease Treatment), By End User (Homecare, Hospitals & Clinics), Forecasts to 2027 About Emergen Research Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. Contact Us:
Michelson Diagnostics Frequently Asked Questions (FAQ)
When was Michelson Diagnostics founded?
Michelson Diagnostics was founded in 2006.
Where is Michelson Diagnostics's headquarters?
Michelson Diagnostics's headquarters is located at 1 Grays Farm Production Village, Kent.
What is Michelson Diagnostics's latest funding round?
Michelson Diagnostics's latest funding round is Series B - II.
How much did Michelson Diagnostics raise?
Michelson Diagnostics raised a total of $15.48M.
Who are the investors of Michelson Diagnostics?
Investors of Michelson Diagnostics include Octopus Ventures, Smith & Nephew, Kent County Council, Newable Ventures, Catapult Ventures and 6 more.
Who are Michelson Diagnostics's competitors?
Competitors of Michelson Diagnostics include CivaTech Oncology, Dilon Technologies, Ikonisys, Upromise, Seno Medical and 7 more.
Compare Michelson Diagnostics to Competitors
Micrima develops a system to improve the detection of breast cancer. The imaging system captures three-dimensional (3D) images through the use of harmless radio waves. The safe, low-cost system enables women of all ages to be screened for breast cancer in GP surgeries, or alternative high street locations, with results that are now comparable with traditional X-ray mammograms. It was founded in 2006 and is based in Bristol, United Kingdom.
Halo Healthcare, formerly NeoMatrix, develops devices that allow women and doctors to promote optimal breast health. The company's premier product, the HALO Breast Pap Test, is a fully automated, non-invasive breast cancer risk assessment device designed for use in the primary care setting as part of an annual well-woman visit. The HALO Breast Pap Test is FDA approved for the collection of nipple aspirate fluid for cytological evaluation. The collected fluid can be used in the determination and/or differentiation of normal versus pre-malignant versus malignant cells.
Manoa Medical develops an advanced method of diagnosis and treatment of breast cancer.
FMI Medical Systems is developing ultra high resolution PET/CT/SPECT diagnostic imaging systems combined with drugs and molecular tracers for earliest detection and monitoring of Alzheimer's, neurodegenerative disorders, and head and neck cancers and breast cancer.
Orison Corporation was founded to design, manufacture and market a ultrasound technology platform for early breast cancer detection and diagnosis. Orison's technology aims to utilize Full Field Digital Ultrasound (FDDU) as an enabler that aims to allow the radiologist, for a time, to view breast tissue in a three dimensional environment. The outcome is earlier detection of breast cancer prior to metastasis, resulting in greater five-year survival rates and decreased treatment costs.
CT Atlantic is an early stage company focused on the identification and development of human oncology